Executives
-
Enyedy Mark JCHIEF EXECUTIVE OFFICER -
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER
-
Lentini ReneeVP & PRIN ACCTG OFFICER
-
Wingrove TheresaSVP OF REGULATORY AFFAIRS
-
Kalofonos IsabelSVP & CHIEF COMMERCIAL OFFICER
-
White LaurenSVP, CFO AND PFO
-
Char DanielSVP & CHIEF LEGAL OFFICER
-
Vasconcelles MichaelEVP R&D & MEDICAL AFFAIRS
?
Vasconcelles Michael
EVP R&D & MEDICAL AFFAIRS
ImmunoGen, Inc.
US, Waltham [HQ]
CIK
1734755
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
1,327
Price per Share :
$31.23
Equivalence :
$41,442.21
Transaction History
-
A1,327 Shares After TransactionValue : $21,245.27$21,245.27Transaction Date : 12/29/23
-
Footnotes
-
-
Footnotes:#1 These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023.#2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023.
-
D0.0 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/12/24
-
Footnotes
-
-
Footnotes:#1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").